Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
Xeris Biopharma Holdings stock price today
$7.321
+3.89
+113.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Xeris Biopharma Holdings stock price monthly change
+45.34%
month
Xeris Biopharma Holdings stock price quarterly change
+45.34%
quarter
Xeris Biopharma Holdings stock price yearly change
+50.77%
year
Xeris Biopharma Holdings key metrics
Market Cap | 501.65M |
Enterprise value | 357.58M |
P/E | -2.84 |
EV/Sales | 3.24 |
EV/EBITDA | -5.10 |
Price/Sales | 2.55 |
Price/Book | 6.22 |
PEG ratio | -0.05 |
EPS | -0.59 |
Revenue | 137.14M |
EBITDA | -50.52M |
Income | -81.84M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -85.86% |
Oper. margin | -74.32% |
Gross margin | 79.47% |
EBIT margin | -74.32% |
EBITDA margin | -36.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXeris Biopharma Holdings stock price history
Xeris Biopharma Holdings stock forecast
Xeris Biopharma Holdings financial statements
Average Price Target
$5.8
Potential downside: -20.77%
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | 25.30M | -26.18M | -103.47% |
|---|---|---|---|
| Mar 2023 | 33.19M | -16.83M | -50.71% |
| Jun 2023 | 38.00M | -19.84M | -52.2% |
| Mar 2024 | 40.63M | -18.98M | -46.71% |
| 2022-11-09 | -0.16 | -0.16 |
|---|---|---|
| 2023-03-08 | -0.06349 | -0.1 |
| 2023-05-09 | -0.08572 | -0.12 |
| Dec 2022 | 328778000 | 315.13M | 95.85% |
|---|---|---|---|
| Mar 2023 | 321360000 | 291.31M | 90.65% |
| Jun 2023 | 328778000 | 315.13M | 95.85% |
| Mar 2024 | 336616000 | 345.79M | 102.73% |
| Jun 2022 | -20.60M | 11.86M | 310K |
|---|---|---|---|
| Mar 2023 | -26.14M | -43.97M | -863K |
| Jun 2023 | -13.74M | 8.45M | 556K |
| Mar 2024 | -20.30M | -19.65M | 35.19M |
Xeris Biopharma Holdings alternative data
| Aug 2023 | 355 |
|---|---|
| Sep 2023 | 355 |
| Oct 2023 | 355 |
| Nov 2023 | 355 |
| Dec 2023 | 355 |
| Jan 2024 | 355 |
| Feb 2024 | 355 |
| Mar 2024 | 377 |
| Apr 2024 | 377 |
| May 2024 | 377 |
| Jun 2024 | 377 |
| Jul 2024 | 377 |
Xeris Biopharma Holdings other data
63.87%
+2.18%
of XERS is owned by hedge funds
100
+12
50.47M
+9.45M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 82449 | 0 |
| May 2024 | 5400 | 0 |
| Aug 2024 | 8800 | 0 |
| Patent |
|---|
Grant Filling date: 31 Jul 2020 Issue date: 20 Sep 2022 |
Application Filling date: 13 May 2021 Issue date: 31 Mar 2022 |
Application STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME Filling date: 25 Jun 2021 Issue date: 30 Dec 2021 |
Application Filling date: 29 Mar 2021 Issue date: 14 Oct 2021 |
Grant Filling date: 6 Aug 2015 Issue date: 28 Sep 2021 |
Grant Filling date: 31 May 2018 Issue date: 1 Jun 2021 |
Grant Filling date: 22 Mar 2016 Issue date: 27 Apr 2021 |
Application Filling date: 23 Jan 2019 Issue date: 4 Feb 2021 |
Application Filling date: 21 Dec 2018 Issue date: 14 Jan 2021 |
Application Filling date: 29 May 2020 Issue date: 3 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris Biopharma: Speculative Buy, Size Your Position Accordingly
Xeris Biopharma Holdings: On Track To Be Cash Flow Positive
Xeris Biopharma's Financial Pathway: Growth Amid Challenges
Xeris Biopharma: Picks And Shovels Play Has Long-Term Growth Potential
Xeris Biopharma: Assessing The Growth And Valuation Disparity
Assertio Holdings: Acquiring Good Products Is The Key To Success
Xeris Biopharma: Q3 Earnings Reveals Strong Growth And Path To Breakeven
Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
-
What's the price of Xeris Biopharma Holdings stock today?
One share of Xeris Biopharma Holdings stock can currently be purchased for approximately $7.32.
-
When is Xeris Biopharma Holdings's next earnings date?
Unfortunately, Xeris Biopharma Holdings's (XERS) next earnings date is currently unknown.
-
Does Xeris Biopharma Holdings pay dividends?
No, Xeris Biopharma Holdings does not pay dividends.
-
How much money does Xeris Biopharma Holdings make?
Xeris Biopharma Holdings has a market capitalization of 501.65M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 447% to 110.25M US dollars. Xeris Biopharma Holdings made a loss 94.66M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.
-
What is Xeris Biopharma Holdings's stock symbol?
Xeris Biopharma Holdings, Inc. is traded on the NASDAQ under the ticker symbol "XERS".
-
What is Xeris Biopharma Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Xeris Biopharma Holdings?
Shares of Xeris Biopharma Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Xeris Biopharma Holdings's key executives?
Xeris Biopharma Holdings's management team includes the following people:
- Mr. Paul R. Edick Chairman & Chief Executive Officer(age: 69, pay: $1,090,000)
- Mr. John P. Shannon Pres, Chief Operating Officer & Director(age: 63, pay: $776,080)
- Ms. Beth P. Hecht J.D. Senior Vice President, Gen. Counsel, Corporation Sec. & Director(age: 61, pay: $588,290)
-
How many employees does Xeris Biopharma Holdings have?
As Jul 2024, Xeris Biopharma Holdings employs 377 workers.
-
When Xeris Biopharma Holdings went public?
Xeris Biopharma Holdings, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
-
What is Xeris Biopharma Holdings's official website?
The official website for Xeris Biopharma Holdings is xerispharma.com.
-
Where are Xeris Biopharma Holdings's headquarters?
Xeris Biopharma Holdings is headquartered at 180 North LaSalle Street, Chicago, IL.
-
How can i contact Xeris Biopharma Holdings?
Xeris Biopharma Holdings's mailing address is 180 North LaSalle Street, Chicago, IL and company can be reached via phone at +84 44455704.
-
What is Xeris Biopharma Holdings stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Xeris Biopharma Holdings in the last 12 months, the avarage price target is $5.8. The average price target represents a -20.77% change from the last price of $7.32.
Xeris Biopharma Holdings company profile:
Xeris Biopharma Holdings, Inc.
xerispharma.comExchange:
NASDAQ
Full time employees:
377
Industry:
Biotechnology
Sector:
Healthcare
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
180 North LaSalle Street
Chicago, IL 60601
Chicago, IL 60601
CIK: 0001867096
ISIN: US98422E1038
CUSIP: 98422E103
